Michael Santillan, PA
Medical · Mission Viejo, CANPI 1861139628
Payments from drug & device makers
Across 468 payments — averaging $24.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$2K
- AbbVie$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Otsuka America Pharmaceutical, Inc.$1K
- Vanda Pharmaceuticals Inc.$1K
- Lundbeck LLC$831
- plus $4K from 18 others
What the payments were for
- Food & beverage$11,499100%
- Education$510%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 60 | $2,121 |
| AbbVie | 56 | $1,325 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 63 | $1,224 |
| Otsuka America Pharmaceutical, Inc. | 49 | $1,150 |
| Vanda Pharmaceuticals Inc. | 34 | $1,016 |
| Lundbeck LLC | 36 | $831 |
| Alkermes, Inc. | 32 | $667 |
| Teva Pharmaceuticals USA, Inc. | 25 | $580 |
| Axsome Therapeutics, Inc. | 14 | $415 |
| Neurocrine Biosciences, Inc. | 15 | $387 |
| Almatica Pharma LLC | 14 | $350 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $251 |
| Corium, LLC | 12 | $243 |
| Ironshore Pharmaceuticals Inc. | 9 | $217 |
| E.r. Squibb & Sons, L.L.C. | 6 | $181 |
| Indivior Inc. | 5 | $118 |
| Bausch Health US, LLC | 5 | $108 |
| Noven Therapeutics, LLC | 5 | $88 |
| Merck | 5 | $76 |
| Supernus Pharmaceuticals, Inc. | 3 | $69 |
| Biogen | 2 | $49 |
| OWP Pharmaceuticals, Inc. | 2 | $46 |
| Sumitomo Pharma America, Inc. | 1 | $21 |
| Tris Pharma Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$274
- INVEGA SUSTENNA$145
- REXULTI$121
- AUSTEDO$120
- Auvelity$112
How this compares
$11,549 in reported general payments places this provider in the 90th percentile of 2,087 medical providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 12 | $114,790 |
| Invega SustennaPaliperidone Palmitate | 28 | $89,988 |
| Austedo XrDeutetrabenazine | 16 | $86,324 |
| VraylarCariprazine Hcl | 14 | $32,626 |
| TrintellixVortioxetine Hydrobromide | 26 | $15,990 |
| LatudaLurasidone Hcl | 12 | $15,814 |
| AdderallDextroamphetamine/Amphetamine | 11 | $7,704 |
| BelsomraSuvorexant | 16 | $7,454 |
| ZoloftSertraline Hcl | 15 | $6,118 |
| Aripiprazole | 73 | $2,692 |
| DepakoteDivalproex Sodium | 11 | $2,342 |
| Lurasidone Hcl | 25 | $1,731 |
| Duloxetine Hcl | 42 | $1,114 |
| Divalproex Sodium ErDivalproex Sodium | 32 | $1,081 |
| Paliperidone ErPaliperidone | 15 | $998 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $580 | $201,11328 claims |
| Johnson & JohnsonInvega Sustenna | $2,121 | $89,98828 claims |
| AbbVieVraylar | $1,325 | $32,62614 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Adderall | $251 | $23,69437 claims |
| MerckBelsomra | $76 | $7,45416 claims |
| Almatica Pharma LLCSertraline Hcl | $350 | $58278 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,087 medical providers in California.
Other medical in Mission Viejo
- Nicola LowreyOrange$655K
- Justin LoveLoma Linda$553K
- David DoriguzziLancaster$514K
- Alison GracomIrvine$467K
- Jeffrey BonnaudLos Angeles$314K
- Ana TorresLaguna Beach$229K
- Heather ParlettRedlands$168K
- Deirdre MoxleyFullerton$149K
- Tri leGardena$127K
- Linda RankLadera Ranch$105K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.